查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球抗凝血酶市场 - 2023-2030年
市场调查报告书
商品编码
1290433

全球抗凝血酶市场 - 2023-2030年

Global Antithrombin Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球抗凝血酶市场在2022年达到了5.45亿美元，预计到2030年将会出现有利可图的增长，达到7.757亿美元。在2023-2030年的预测期内，全球抗凝血酶市场预计将呈现4.6%的复合增长率。

心血管疾病发病率的增加，治疗遗传性抗凝血酶缺乏症对抗凝血酶疗法的需求上升，抗凝血酶领域的研究和开发活动不断增加，以及外科手术中越来越多地采用抗凝血酶，是影响全球抗凝血酶市场的一些趋势。

例如，加州大学旧金山分校的研究人员在《科学转化医学》杂志上进行的一项研究，抗凝血酶缺乏症是一种遗传性疾病，会导致血液凝固。科学家们创造了一种基因编辑疗法，利用CRISPR-Cas9基因编辑技术将受影响患者的血细胞转化为多能干细胞（iPSCs）来治疗这种疾病。

然后，改变后的iPSCs被转化为肝细胞，即制造抗凝血酶的肝细胞。这些肝细胞随后被植入有抗凝血酶缺陷的小鼠体内，减少血凝块的形成。这项工作展示了CRISPR-Cas9修复基因异常的潜力，为开发遗传性抗凝血酶缺乏症的创新疗法带来了希望。

抗凝血酶（AT）是一种在肝脏中合成的464个氨基酸的糖蛋白。它有三个二硫键和四个糖基化位点。抗凝血酶是一个丝氨酸家族成员，具有丝氨酸蛋白酶抑制剂的功能。它能与参与凝血过程的许多蛋白酶结合并使其失活。这些蛋白酶包括凝血酶、Xa因子、IXa因子、XIa因子和XIIa因子。AT的抑制活性延伸到了蛋白C和S，这两种蛋白都是重要的抗凝血蛋白。

静脉血栓栓塞症（vte）发病率的上升，各种临床场合对抗凝血酶作为治疗剂的需求增长，以及新的抗凝血酶产品和疗法的开发，是预计在预测期内推动全球抗凝血酶市场的因素。

新的抗凝血酶产品的开发，例如，Octapharma公司正在进行一项临床试验，以评估Atenativ对进行手术或分娩的先天性抗凝血酶缺乏者的疗效。这些都是影响全球抗凝血酶市场的因素。

市场动态

心血管疾病发病率的增加推动了全球抗凝血酶市场的增长。

在全球范围内，心血管疾病是导致死亡和残疾的一个主要原因。它的发展受到几个变量的影响，包括高血压、高胆固醇、吸烟和肥胖。

例如，根据美国心脏协会2023年的心脏病和中风统计报告，2020年美国有928,741人死于心血管疾病，其中冠心病（CHD）占死亡人数的41.2%，其次是中风。因此，由于这些原因，心血管疾病发病率的增长将在预测期内推动全球抗凝血剂市场的发展。

抗凝血酶产品的高成本阻碍了全球抗凝血酶市场的增长。

各种因素导致了抗凝血酶药物的高成本。与合成药物相比，由于它们是由汇集的人类血浆制成的，所以一开始就是昂贵的原始材料。其次，由于需要高度纯化和浓缩，抗凝血酶产品的生产总体上更加复杂和昂贵。

此外，与其他疗法相比，抗凝血酶药品的市场较小，竞争也较少，这就导致了价格竞争不激烈。最后但并非最不重要的是，抗凝血酶产品主要治疗一种被称为严重抗凝血酶缺乏症的罕见疾病，这进一步限制了全球抗凝血酶的市场规模，并导致价格上涨。

COVID-19影响分析

COVID-19的大流行对全球抗凝血酶市场产生了重大影响。由于外科手术和静脉血栓栓塞症（VTE）等疾病诊断的减少，抗凝血酶的需求也随之减少。尽管有这些障碍，市场预计在未来仍会增长。有几个原因，如心血管疾病的发病率上升，对抗凝血酶治疗的好处有更多的了解，以及在创造新型抗凝血酶药物方面的改进，将影响这种扩张。

俄罗斯-乌克兰冲突分析

俄罗斯和乌克兰之间持续的冲突伤害了全球抗凝血酶市场，使其供应减少。对俄罗斯的制裁，供应链的打嗝，以及产量的减少只是造成这种下降的几个原因。由于供应量减少，抗凝血酶的成本增加，使患者更难购买这种药物。

由于一些情况，冲突也导致了对抗凝血酶需求的下降。获得医疗服务的机会减少了，可花的钱也少了，受暴力影响的人更加恐惧和担心。预计俄乌冲突将对世界抗凝血剂市场产生短期的不利影响。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按用途分类的摘要
  • 按类型分类
  • 按给药途径分类
  • 按来源分类的摘要
  • 按地区分类

第4章：动态变化

  • 影响因素
    • 驱动因素
      • 心血管疾病发病率的增加推动了全球抗凝血酶市场的增长。
    • 限制因素
      • 抗凝血酶产品的高成本阻碍了全球抗凝血酶市场的增长。
    • 机会
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第六章：COVID-19分析

  • 对COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • 后COVID-19及未来的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：按用途分类

  • 治疗学
  • 诊断学
  • 研究领域
  • 其他领域

第九章：按类型划分

  • 抗凝血剂
  • 抗血小板
  • 溶栓药物

第十章：按给药途径分类

  • 口服
  • 肠外

第十一章：按来源分类

  • 人类
  • 重组山羊奶
  • 其他来源

第十二章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第13章 ：竞争格局

  • 竞争格局
  • 产品标杆
  • 公司份额分析
  • 主要发展和战略

第十四章：公司简介

  • CSL Limited
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • Grifols SA
  • Takeda Pharmaceuticals
  • Octapharma AG
  • LFB USA
  • Axis-Shield Plc
  • Siemens AG
  • Thermo Fisher Scientific
  • Lee Biosolutions Inc.
  • BDI Pharma

第十五章 ：附录

简介目录
Product Code: PH4035

Market Overview

The Global Antithrombin Market reached US$ 545 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 775.7 million by 2030. The global antithrombin market is expected to exhibit a CAGR of 4.6% during the forecast period 2023-2030.

The increasing prevalence of cardiovascular diseases, rising demand for antithrombin therapy in the treatment of hereditary antithrombin deficiency, growing research and development activities in the field of antithrombin, and growing adoption of antithrombin in surgical procedures are some of the antithrombin market trends that will influence the Global Antithrombin Market.

For instance, a study conducted by researchers at the University of California, San Francisco, published in the journal Science Translational Medicine, Antithrombin deficiency is a hereditary disease that can lead to blood clotting. Scientists have created a gene-editing therapy that transforms blood cells from afflicted patients into pluripotent stem cells (iPSCs) using the CRISPR-Cas9 gene-editing technology to treat this disease.

Then altered iPSCs are transformed into hepatocytes, liver cells that make antithrombin. These hepatocytes are subsequently implanted into mice with antithrombin deficiencies, reducing blood clot formation. This work demonstrates CRISPR-Cas9's potential for repairing genetic abnormalities and holds hope for developing innovative therapeutics for hereditary antithrombin deficiency.

Antithrombin (AT) is a 464 amino acid glycoprotein synthesized in the liver. It has three disulfide bonds and four glycosylation sites. AT is a serpin family member that functions as a serine protease inhibitor. It can bind to and deactivate numerous proteases involved in the coagulation process. Among the proteases are thrombin, factor Xa, factor IXa, factor XIa, and factor XIIa. AT's inhibitory activity extends to proteins C and S, both of which are essential anticoagulant proteins.

The rising incidence of venous thromboembolism (vte), growing demand for antithrombin as a therapeutic agent in various clinical settings, and development of new antithrombin products and therapies are the factors expected to drive the global antithrombin market over the forecast period.

Development of new antithrombin product, for instance, Octapharma, is conducting a clinical trial to evaluate the efficacy of Atenativ in individuals having surgery or delivery who have congenital antithrombin deficiency. These are the factors influencing the global antithrombin market.

Market Dynamics

Increased Prevalence of Cardiovascular Disease is Driving the Global Antithrombin Market Growth.

On a global level, cardiovascular disease is a major cause of mortality and disability. Its development is influenced by several variables, including as high blood pressure, high cholesterol, smoking, and obesity.

For instance, according to the American Heart Association's Heart Disease and Stroke Statistics report of 2023, 928,741 deaths were seen in the U.S. in 2020 for cardiovascular disease, in which coronary heart disease (CHD) held 41.2% of deaths, followed by strokes. Therefore owing to these reasons, the growing prevalence of cardiovascular disease will drive the global antithrombin market over the forecast period.

The High Cost of Antithrombin Products is Hampering the Growth of the Global Antithrombin Market.

Various factors contribute to the higher cost of antithrombin drugs. In contrast to synthetic medications, they start off as expensive source materials since they are made from pooled human plasma. Second, the production of antithrombin products is more complicated and expensive overall due to the high degrees of purification and concentration required.

Moreover, compared to other therapies, antithrombin medicines have a smaller market and less competition, which results in less price competition. Last but not least, antithrombin products mainly treat a rare disease termed severe antithrombin deficiency, further limiting the global antithrombin market size and contributing to higher prices.

COVID-19 Impact Analysis

The COVID-19 pandemic has had significant effects on the Global Antithrombin Market. Antithrombin demand has decreased due to a decline in surgical operations and diagnosis of illnesses such as venous thromboembolism (VTE). The market is expected to grow in the future despite these obstacles. Several reasons, such as the rising incidence of cardiovascular disorders, more knowledge of the benefits of antithrombin therapy, and improvements in the creation of novel antithrombin medicines, will influence this expansion.

Russia-Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine has hurt the global antithrombin market, which has reduced its supply. Sanctions on Russia, supply chain hiccups, and decreased output are just a few of the causes that contributed to this fall. Antithrombin costs have increased due to the reduced availability, making it more difficult for patients to purchase the medication.

Due to several circumstances, the conflict has also led to a decline in the demand for antithrombin. There is less access to healthcare services, less money to spend, and more fear and worry among those impacted by the violence. The Russia-Ukraine conflict is anticipated to have a short-term detrimental effect on the world antithrombin market.

Segment Analysis

The Global Antithrombin Market is segmented based on usage, source, route of administration, type, and region.

The Parenteral segment is expected to hold a dominant position for the global antithrombin market over the forecast period.

The Parenteral route accounted for the highest market share, accounting for approximately 64.4% of the antithrombin market in 2022. The preferred route of administration for antithrombin drugs in the Parenteral route is intravenous. Because the intravenous injection is frequently utilized to deliver antithrombin into the blood circulation swiftly, it provides prompt and effective therapy, it is commonly preferred for individuals with severe antithrombin insufficiency.

Thrombate III, a pure human antithrombin III product, is a sterile and stable lyophilized preparation. It is used to treat both primary and acquired antithrombin insufficiency. It is made from pooled units of human plasma collected from healthy donors. Thrombate III contains no preservatives and should only be taken intravenously. Thus, owing to the above factors, the market segment is expected to hold the largest market share for global antithrombin market over the forecast period.

Geographical Analysis

North America Holds a Dominant Position in the Global Antithrombin Market.

North America is expected to hold around 38.8% of the total market share throughout the forecast period, as the chance of having thrombotic illnesses such as deep vein thrombosis (DVT), pulmonary embolism, and stroke rises as people age. Geriatric patients may have several comorbidities, surgeries, and limited mobility, all of which increase their risk of blood clot development. With the baby boomer generation approaching retirement age and beyond, the United States has a considerable aging population.

For instance, according to the United States Census Bureau's 2023 report, the 2021 American Community Survey indicated 55,892,014 persons aged 65 and older in the U.S., or 16.8% of the total population of 331,893,745.

Moreover, the increasing awareness about the benefits of antithrombin therapy and the rising number of patients undergoing surgery, also the presence of a major market player in the region, is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma, among others.

Why Purchase the Report?

  • To visualize the Global Antithrombin Market segmentation based on the usage, type, route of administration, source, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of antithrombin market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Antithrombin Market Report would Provide Approximately 49 Tables, 53 Figures, And 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Usage
  • 3.2. Snippet by Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Source
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased Prevalence of Cardiovascular Disease is Driving the Global Antithrombin Market Growth.
    • 4.1.2. Restraints
      • 4.1.2.1. The High Cost of Antithrombin Products is Hampering the Growth of the Global Antithrombin Market.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Usage

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 8.1.2. Market Attractiveness Index, By Usage
  • 8.2. Therapeutics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostics
  • 8.4. Research
  • 8.5. Other

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Anticoagulant*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Antiplatelet
  • 9.4. Thrombolytic Drug

10. By Route of Administration

    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.1.2. Market Attractiveness Index, By Route of Administration
  • 10.2. Oral*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Parenteral

11. By Source

    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.1.2. Market Attractiveness Index, By Source
  • 11.2. Human*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Recombinant Goat Milk
  • 11.4. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.7.1. The U.S.
      • 12.2.7.2. Canada
      • 12.2.7.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.7.1. Germany
      • 12.3.7.2. The U.K.
      • 12.3.7.3. France
      • 12.3.7.4. Italy
      • 12.3.7.5. Spain
      • 12.3.7.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.7.1. Brazil
      • 12.4.7.2. Argentina
      • 12.4.7.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. CSL Limited*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Grifols SA
  • 14.3. Takeda Pharmaceuticals
  • 14.4. Octapharma AG
  • 14.5. LFB USA
  • 14.6. Axis-Shield Plc
  • 14.7. Siemens AG
  • 14.8. Thermo Fisher Scientific
  • 14.9. Lee Biosolutions Inc.
  • 14.10. BDI Pharma

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us